UNICEF and Aerogen have agreed to a two-year partnership in support of UNICEF’s work in the areas of global vaccine equity and the health of newborns, according to a company news release.
In 2021, Aerogen has committed €50,000 to go towards funding UNICEF’s delivery of 2 billion COVID-19 vaccines to the most vulnerable families, health workers and high-risk people on our planet. As the largest single vaccine buyer in the world, UNICEF has a unique and longstanding expertise in procurement and logistics to help children in need.
UNICEF is the key implementing partner for the COVAX Facility, a global effort led by ACT-A partners Gavi, WHO and CEPI to aid the equitable distribution of COVID-19 vaccines. UNICEF was asked to come on board because of its expertise in procuring half the world’s vaccines for children under 5 every year. We are committed to achieving the historic target of delivering two billion vaccines in 2021, with a focus on 92 low- and middle-income countries. COVAX has already delivered 88.4 million doses to 131 countries and territories.
“We are proud to launch this partnership with UNICEF today,” said Aerogen CEO John Power. “As an international brand we are excited to be collaborating with a global organization which shares our commitment to making a difference in communities that most need support.. We recognize the importance of vaccine equity, and we are pleased to be able to support UNICEF as they work to support the most vulnerable newborns.”
In the second year of the partnership Aerogen will fund work by UNICEF and partners to help save the lives of mothers and their newborns.
UNICEF Ireland Executive Director, Peter Power, welcomed the announcement: “UNICEF is the world’s largest humanitarian organization for children with operations in over 190 countries. UNICEF relies significantly on the private sector to help fund our life-saving and life-changing operations for children and we are pleased to welcome Aerogen’s generous contribution to this work.”
Source: Aerogen
